Alexandria Hammond
Stock Analyst at B of A Securities
(1.82)
# 2,989
Out of 4,829 analysts
14
Total ratings
60%
Success rate
-5.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Upgrades: Buy | $35 → $63 | $39.85 | +58.09% | 2 | Jan 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $527.78 | +117.89% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $22.28 | +12.21% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $24.25 | +64.95% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $75.97 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $734.57 | +36.13% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $154.22 | +23.20% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $96.91 | +13.51% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $46.45 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $118.17 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $184.60 | +11.05% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $299.69 | -49.95% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $7.71 | +289.36% | 1 | Apr 22, 2024 |
Akero Therapeutics
Jan 30, 2025
Upgrades: Buy
Price Target: $35 → $63
Current: $39.85
Upside: +58.09%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $527.78
Upside: +117.89%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $22.28
Upside: +12.21%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $24.25
Upside: +64.95%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $75.97
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $734.57
Upside: +36.13%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $154.22
Upside: +23.20%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $96.91
Upside: +13.51%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $46.45
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $118.17
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $184.60
Upside: +11.05%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $299.69
Upside: -49.95%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $7.71
Upside: +289.36%